Fosun International expects profit attributable to owners of the parent for the first half of 2026 to range from approximately RMB1.5 billion to RMB1.8 billion, representing an increase of approximately 127% to 172% compared with the same period last year.
The company attributed the anticipated increase to the resilience of its core industries, improvements in operational quality and a significant rise in industrial operation profit.
Pharmaceuticals and insurance remained two major contributors to the Group’s performance during the period, with Fosun Pharma continuing to advance its innovative drug pipeline and regulatory activities.
Fosun Pharma, a core subsidiary of Fosun International’s Health segment, recorded operating revenue of RMB10.073 billion in the first quarter of 2026, an increase of 6.93% year-on-year.
Net profit attributable to shareholders of the parent reached RMB871 million, up 13.87% year-on-year. Excluding non-recurring gains and losses, net profit attributable to shareholders of the parent increased by 21.96%.
During the first quarter, new drug applications for four innovative drugs were accepted, while 14 clinical trial applications for innovative drugs were approved by regulatory authorities in China and overseas.
In June 2026, China’s National Medical Products Administration approved a new indication for Henlius’ anti-PD-1 monoclonal antibody HANSIZHUANG for the perioperative treatment of gastric cancer.
The drug subsequently received European Commission approval in combination with chemotherapy as a first-line treatment for adult patients with unresectable, locally advanced or metastatic squamous non-small cell lung cancer.
Fosun’s innovative drug pipeline also includes HLX43 and HLX22, which the company said are progressing through further development and regulatory milestones.
Fosun International’s positive profit alert follows one-off non-cash impairment provisions relating to real estate projects and certain non-core businesses in the 2025 financial year.
The Group has continued to exit non-core assets while strengthening investment and operational capabilities across its main businesses.
Fosun International has set longer-term financial objectives that include gradually restoring annual profit to approximately RMB10 billion, generating RMB60 billion in cash returns at Group level and reducing total debt to below RMB60 billion.
Between 30 March and 10 July 2026, Fosun International repurchased approximately 53.41 million shares for a total consideration of approximately HKD216 million.
